Humalog Mix50 (Insulin Lispro)

Humalog Mix50 is indicated for the management of hyperglycemia in adults with diabetes mellitus.

• Treatment of type 1 diabetes when a mixed insulin regimen is preferred.
• Treatment of type 2 diabetes in patients who require both rapid and intermediate insulin action.
• Part of a basal‑bolus insulin strategy to mimic physiological insulin patterns.
• Use in combination with oral antidiabetic agents when additional glucose control is needed.
• Suitable for patients who need a convenient mixed‑insulin formulation to reduce injection frequency.

• Insulin lispro binds to insulin receptors on muscle and adipose tissue, activating the receptor’s intrinsic tyrosine kinase activity. This triggers a cascade that promotes translocation of GLUT‑4 transporters to the cell surface, enhancing glucose uptake. It also suppresses hepatic glucose production and facilitates glycogen synthesis, thereby lowering circulating blood glucose levels. The mixed formulation provides an initial rapid‑acting phase followed by a prolonged intermediate‑acting effect.

Adverse reactions to Humalog Mix50 can vary in frequency and severity.

Common

• Mild hypoglycemia, especially if meals are delayed or missed.
• Injection site redness, swelling, or itching.
• Lipodystrophy or localized fat loss at the injection site.
• Transient weight gain due to fluid retention.

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures.
• Allergic reactions such as urticaria, angioedema, or anaphylaxis.
• Persistent edema or heart failure exacerbation in susceptible individuals.

When using Humalog Mix50, several safety considerations should be observed.

• Monitor blood glucose regularly to adjust dose and avoid hypoglycemia.
• Use caution in patients with renal or hepatic impairment, as insulin clearance may be reduced.
• Assess cardiovascular status; rapid‑acting insulin can precipitate cardiac events in unstable patients.
• Pregnancy and lactation status should be evaluated, as safety data are limited.
• Educate patients on proper injection technique to minimize lipodystrophy.
• Store the product according to manufacturer instructions to maintain potency.

Humalog Mix50 may interact with other medications, affecting glucose control.

Avoid

• Concurrent use of other rapid‑acting insulins or high‑dose sulfonylureas, which can cause severe hypoglycemia.
• Beta‑blockers that mask hypoglycemia symptoms.

Use with caution

• ACE inhibitors or ARBs, which may potentiate insulin’s glucose‑lowering effect.
• Corticosteroids, which can increase insulin resistance.
• Thiazide diuretics, which may raise blood glucose levels.
• Alcohol, which can cause unpredictable glucose fluctuations.
• Medications that affect renal function, altering insulin clearance.